Grail, Inc. · NASDAQ:GRAL
Grail — Technical Presentation (June 2023)
12 slides from Grail's technical presentation, June 2023
Slide 1: Methylated DNA Biomarkers and Incident Cancer in the ACS CPS-3 Cohort
Methylated DNA Biomarkers and Incident Cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) Cohort Alpa V. Patel, PhD Abstract 3004 The copyright for the presentation slides remains with the authors/presenter. Permission must be obtained for reuse. PRESENTED BY:
Slide 2: Cancer Signal Detection In Blood Is Determined By Cancer Biology
2 Cancer Signal Detection In Blood Is Determined By Cancer Biology1-4 Clinical Cancer Shedding Cancer signal detected diagnosis Post-diagnostic onset onset (~limit of detection) (conventional) treatment/monitoring Pre-clinical detectable window Shedding window Blood draw window No detection Detectio
Slide 3: The ACS CPS-3 Biobank Provides An Opportunity To Explore Preclinical Cancer Biology
3 The ACS CPS-3 Biobank Provides An Opportunity To Explore Preclinical Cancer Biology ACS CPS-31 is a large prospective cohort study of 300K volunteers: ● Not initially diagnosed with cancer who gave blood samples and were followed for incident cancer ● With sufficient biobanked plasma volume availa
Slide 4: ACS CPS-3/GRAIL Study Design Subsampled To Matched Cohorts
4 ACS CPS-3/GRAIL Study Design Subsampled To Matched Cohorts INCLUSION • 30+ years old • No history of cancer prior to enrollment INITIAL • Plasma sample • Were not lost to follow-up within 3 years EXCLUSIONS volume and quality (for those without cancer diagnosis) Qualified Participants for Retrospe
Slide 5: CPS-3 Cohort Demographics Differ From Standard Populations By Cancer Risk Factors
5 CPS-3 Cohort Demographics Differ From Standard Populations By Cancer Risk Factors • Lower cancer Participant Selected Selected Selected Characteristics* Cancer Non-Cancer Total incidence and (n=1383) (n=1371) (n=2754) mortality rates N (Cohort population) 2472 230,050 232,522 than SEER- expected1
Slide 6: Both Cancer Characteristics And Time Between Blood Draw And Diagnosis Affect Detection Rate
6 Both Cancer Characteristics And Time Between Blood Draw And Diagnosis Affect Detection Rate • Lower overall detection rate than expected from SEER was observed as expected in a population with reduced rates of deadly cancers relative to other cancers* • Aggressive cancers (selected types) had high
Slide 7: The Accuracy Of Prediction Of Cancer Signal Origin (CSO) Was High
7 The Accuracy Of Prediction Of Cancer Signal Origin (CSO) Was High Top 1 CSO overall accuracy of prediction Top 5 CSO* was: Head and • 95% (95% CI: 90.4%, 100.0%) in Year 1 Neck Lymphoid • 88% (95% CI: 76.2%, 94.4%) in Year 2 Neoplasm Breast • 81% (95% CI: 57.0%, 93.4%) in Year 3 ♀ Plasma Cell Neop
Slide 8: Detection Rates Are Consistent With ~1 Year Average Detectable Window
8 Detection Rates Are Consistent With ~1 Year Average Detectable Window 323 days 40% 991 days average time between of cancers detected lead time for a blood draw and diagnosis found beyond 1 year colorectal cancer at among those detected regional stage Cancers up to the end of the study period were
Slide 9: The Shedding Rate Of Eventually Fatal Cancers Suggests Potential To Intervene Early And Predict Risk
9 The Shedding Rate Of Eventually Fatal Cancers Suggests Potential To Intervene Early And Predict Risk ● The high efficiency of detecting eventually fatal cancers in this non-interventional study has implications for risk of death ○ This suggests overdiagnosis of indolent cancers is not likely ○ Ind
Slide 10: Conclusions: Explored Cancer Biology In A Relatively Low-Risk Adult Population
10 Conclusions: Explored Cancer Biology In A Relatively Low-Risk Adult Population ● The cohort was comprised of healthy, largely female and never smoker volunteers aged 30-65 at lower-than-average risks of overall cancer and particularly, deadly cancers ● Because the cohort banked analyzable plasma,
Slide 11: Conclusions: Rapid Changes In Cancer Biology Occur Before Clinical Diagnosis
11 Conclusions: Rapid Changes In Cancer Biology Occur Before Clinical Diagnosis ● Cancer signals were detected in preclinical blood draws ○ Potential for limits to signal due to plasma processing differences ○ With high efficiency for eventually fatal cancers ■ Underscoring the need for earlier inte
Slide 12: Thank You!
12 Thank You! Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the author of this slide deck. For more information, please contact: • Alpa Patel alpa.patel@cancer.org • Christina Clarke cclarke@grailbio.co